HRPT2/Parafibromin Antibody (Rabbit mAb) [E14N24]

Catalog No.: F5479

    Application: Reactivity:
    • Lane 1: HeLa, Lane 2: Caco-2, Lane 3: HepG2
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:1000
    1:500
    Application
    WB, IHC, FCM
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Mouse, Rat, Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    61 kDa 60 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Rat brain tissue; Mouse brain tissue; Human kidney tissue; Human fetal kidney tissue; Human parathyroid carcinoma tissue; HeLa cells; Caco-2 cells; HepG2 cells
    ネガティブコントロール Human clear cell renal cell carcinoma

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/Nuclear Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/Nuclear Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/Nuclear Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    HRPT2/Parafibromin Antibody (Rabbit mAb) [E14N24] detects endogenous levels of total HRPT2/Parafibromin protein.
    タンパク質の局在
    細胞核
    Uniprot ID
    Q6P1J9
    Clone
    E14N24
    Synonym(s)
    C1orf28, HRPT2, CDC73, Parafibromin, Cell division cycle protein 73 homolog, Hyperparathyroidism 2 protein
    Background
    Parafibromin, the protein product of the HRPT2/CDC73 tumor suppressor gene, is an evolutionarily conserved component of the human PAF1 complex that links RNA polymerase II transcription elongation and 3′ end processing to chromatin modification and repression of proto‑oncogene and cell‑cycle–promoting transcriptional programs. The protein localizes predominantly to the nucleus and associates with human orthologs of yeast Paf1 complex subunits, including PAF1, LEO1, CTR9, and SKI8, through a C‑terminal region that is frequently truncated or deleted by germline and somatic HRPT2 mutations; this C‑terminal domain is required for stable interaction with Ser2‑ and Ser5‑phosphorylated forms of the RNA polymerase II CTD and positions parafibromin within elongating transcription complexes that coordinate recruitment of RNA processing factors and chromatin regulators. As part of the PAF1 complex, parafibromin participates in coupling transcription elongation to histone H2B monoubiquitination and histone H3 lysine 4 and 79 methylation, and it additionally recruits or cooperates with histone‑modifying enzymes to establish repressive chromatin at specific growth‑regulatory loci: parafibromin promotes histone H3 lysine 9 methylation and reduced H3 acetylation at the cyclin D1/CCND1 promoter, and it also contributes to repression of the c‑MYC proto‑oncogene, providing a direct mechanistic basis for its anti‑proliferative activity. Functional disruption of parafibromin by RNA interference accelerates S‑phase entry and increases expression of cyclin D1, whereas transient overexpression of wild‑type but not cancer‑associated mutant parafibromin inhibits cell proliferation and represses cyclin D1, linking intact HRPT2/CDC73–PAF1 interactions and parafibromin‑dependent chromatin remodeling to restraint of G1/S progression. Parafibromin also integrates canonical Wnt/β‑catenin signaling with transcriptional outputs: dephosphorylated parafibromin associates with β‑catenin and binds TCF/LEF‑responsive promoters to act as a transcriptional coactivator for Wnt target genes such as c‑MYC, CYCLIN D1, and AXIN2, whereas phosphorylated parafibromin favors repressive complexes, indicating that its phosphorylation state dictates a switch between tumor‑suppressive repression and context‑dependent Wnt coactivation at shared growth‑control loci. These dual roles at c‑MYC and CCND1 illustrate that parafibromin does not simply silence proliferation genes globally but instead modulates their expression through promoter‑ and pathway‑specific chromatin mechanisms that are sensitive to upstream morphogen inputs. Germline inactivation of HRPT2/CDC73 underlies hyperparathyroidism–jaw tumor syndrome and is strongly associated with parathyroid carcinoma, while somatic mutations and loss of parafibromin expression occur in sporadic parathyroid cancers and subsets of other endocrine and non‑endocrine tumors, and parafibromin immunonegativity serves as a diagnostic marker that distinguishes malignant from benign parathyroid neoplasms. Beyond parathyroid tissue, deregulated parafibromin expression and altered CDC73 transcription, including repression by Wilms’ tumor suppressor WT1, link this factor to broader oncogenic contexts, and emerging data connect parafibromin–PAF1 complexes to leukemogenic MLL fusion transcriptional programs and to viral host interactions.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください